Here’s how much weight-loss drugs Wegovy, Zepbound and Foundayo cost — and how to pick the best GLP-1 for you

The burgeoning market for GLP-1 weight-loss drugs has brought both hope and complexity. MarketWatch's analysis highlights the varying costs and efficacy profiles of key players like Wegovy (semaglutide), Zepbound (tirzepatide), and the lesser-known, potentially compounding-derived Foundayo. While prices for branded options such as Wegovy and Zepbound typically hover around $1,000 to $1,300 per month without insurance, Foundayo, sometimes offered through compounding pharmacies, may present a more affordable alternative, though regulatory oversight and consistency can vary. This financial disparity largely shapes patient access and choice. For investors, the diverse pricing strategies and insurance coverage trends for these drugs are critical. Pharmaceutical companies with strong pipelines and proven reimbursement models are likely to see sustained growth. However, the rise of potentially cheaper, compounding pharmacy-produced alternatives could introduce competitive pressures, prompting a closer look at patent protections and manufacturing capacities. The high demand for these drugs means that even with significant out-of-pocket costs, their market penetration continues to expand, driven by efficacy. Patients must weigh not only cost but also clinical effectiveness, potential side effects, and insurance coverage when selecting a GLP-1. Investors, conversely, should monitor drug manufacturers' quarterly earnings calls for updates on production capacity, insurance negotiations, and emerging competitive threats, which will be the next major market catalysts.